VEGFA and cancer: While ORR was similar between the arms (24% and 25%), 89% of patients treated with Bev had a duration of response (DOR) ≥6 months compared to 47% without Bev, suggesting there is potentially a more durable anti-cancer effect with the addition of VEGF inhibition to ICI [58].